People areflocking to Discovery because they realize innovation is critical to aprosperous Ontario.”Almost 300 exhibitors will be on site at the Metro Toronto ConventionCentre May 11th and 12th, providing a rare glimpse into the province’sfuture innovation economy. “It brings together theleaders who actually drive new technologies to market. TORONTO, ONTARIO, May 08 (MARKET WIRE) — It seems innovation is recession-proof if attendance at Ontario Centresof Excellence (OCE) annual conference, Discovery 09 is anything to go by.The event which kicks off May 11 and features almost 2,100 businessleaders, investors, entrepreneurs, scientists, researchers and studentspromises to be a huge success.”In the current economic climate, innovation is crucial to Ontario’ssuccess and global competitiveness, and that’s what Discovery 09 is allabout,” said OCE President and CEO Mark Romoff.”Discovery is a remarkable phenomenon,” he added. OCE is funded by the government of Ontario and is a keypartner in delivering Ontario’s Innovation Agenda.Contacts:Ontario Centres of ExcellenceSean McNeelyManager, Media Relations & Communications416-861-1092 ext Copyright 2009, Market Wire, All rights reserved.-0-.

In doing this, OCEfosters the training and development of the next generation of innovatorsand entrepreneurs and is a key partner with Ontario’s industry,universities, colleges, research hospitals, investors and governments.OCE’s Centres work in communications and information technology, earthand environmental technologies, energy, materials and manufacturing andphotonics. Click Consult isfully certified by Google AdWords, Microsoft adExcellence, the InternetAdvertising Bureau, SEOCertification and TopSEOs .To view the accompanying photo, please visit the following link: http:// Consult0845 205 0292 2009, Market Wire, All rights reserved.-0-. With over 35 Staff in Cheshire and London, Click Consult hasover 200 PPC and SEO clients in every major industry. Establishedin 2003, Click Consult is a leading provider of Search Engine Marketing(SEM) solutions, including Pay Per Click (PPC) Campaigns, Content andBanner Advertising, Search Engine Optimisation, Affiliate Marketing,Shopping Feeds, Website Design and Development, E-Mail Marketing andOnline PR. Our current client wins reflect ourachievements and April 2009 has been one of most successful monthssigning several Blue Chip & SME organizations.For more details about SEO Consult, please visit our website or call 0845 205 0292.About SEO Consult:SEO Consult is the specialist SEO division of Click Consult. “We are always looking for ways in which to improveour services and we believe that our dedication to providing effectiveand comprehensive SEO services which are proven to bring great results iswhat sets us apart in the UK SEO industry, our transparency is what setsSEO Consult apart providing a detailed online reporting suite for allmonthly SEO activities completed. Theassessment is carried out for each company by collating data such as theaverage time frame in which organic first page results are achieved forSEO clients, the average return on investment, price comparisons withother agencies on like-for-like services, customer support, clientproblem resolution and also takes into account feedback from at leastthree SEO clients to verify the quality of overall SEO services.”To win this award for the sixth month in a row is a testament to ourethos here at SEO Consult,” Matt Bullas, Managing Director of SEOConsult, comments.

CHESHIRE, ENGLAND, May 08 (MARKET WIRE) — Editors Note: A photo is included with this press release.TopSEOs, the independent authority on search vendors, have ranked SEOConsult, the UK’s leading Search Engine Optimisation (SEO) company, asthe UK’s Number 1 Organic SEO Company for the sixth consecutive month.Currently, SEO Consult rank 1st on Google.co.uk for the search term”Search Engine Optimization” and 2nd for “SEO,” correct today 07-05-09.The award is the result of a monthly evaluation by TopSEOs of 300UK-based Search Engine Optimisation agencies on several importantindustry criteria, ensuring that the company scooping the top spot offerscomprehensive services which cover multiple industry angles. 137944 May 2009SOURCENovo NordiskMedia: Ambre Morley, +1-609-514-8400, or Investors: Hans Rommer, +1-609-919-7937. For globalinformation, visit novonordisk ; for United States information, visit more information on the Ochsner Medical Center, go to (C) Novo Nordisk Inc. Its ADRsare listed on the New York Stock Exchange under the symbol ‘NVO’. Novo Nordisk’s Bshares are listed on the stock exchanges in Copenhagen and London. Novo Nordisk’s business isdriven by the Triple Bottom Line: a commitment to economic success,environmental soundness, and social responsibility to employees and customers.With headquarters in Denmark, Novo Nordisk employs more than 27,000 employeesin 81 countries, and markets its products in 179 countries. In addition to diabetes care, Novo Nordiskhas a leading position within areas such as hemostasis management, growthhormone therapy, and hormone therapy for women.

The company has the broadest diabetes productportfolio in the industry, including the most advanced products within thearea of insulin delivery systems. Less common, but more serious are severe cases ofgeneralized allergy, including anaphylactic reaction, which may be lifethreatening.Levemir(R) is a registered trademark of Novo Nordisk A/S.About Novo NordiskNovo Nordisk is a healthcare company with an 86-year history of innovation andachievement in diabetes care. The dose of Levemir(R) may need to beadjusted in patients with renal or hepatic impairment.Other adverse events commonly associated with insulin therapy may includeinjection site reactions (on average, 3 percent to 4 percent of patients inclinical trials) such as lipodystrophy, redness, pain, itching, hives,swelling, and inflammation. Dose and timingof administration may need to be adjusted to reduce the risk of hypoglycemiain patients being switched to Levemir(R) from other intermediate orlong-acting insulin preparations.

Insulinmay cause sodium retention and edema, particularly if previously poormetabolic control is improved by intensified insulin therapy. Levemir(R)should not be diluted or mixed with any other insulin preparations. Hester himself rightly flags up that there are moreheadwinds to come There will be further losses as the recessiondeepens Net interest margins are likely to remain compressed. Whilethe banks may get away with what they term asset pricing (higherinterest charges on our loans), it will be a while — if ever –before their funding costs return to pre-crunch levels.